Over the past decade, whole genome sequencing and other'omics' technologies have
defined pathogenic driver mutations to which tumor cells are addicted. Such addictions …

Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment
agents that combines the selectivity of targeted treatment with the cytotoxic potency of …

Folate receptor α (FRα) came into focus as an anticancer target many decades after the
successful development of drugs targeting intracellular folate metabolism, such as …

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin
in Patients With Advanced Malignanc Page 1 Phase I Pharmacokinetic and Pharmacodynamic …

Background Trastuzumab duocarmazine is a novel HER2-targeting antibody–drug
conjugate comprised of trastuzumab covalently bound to a linker drug containing …

Abstract Heat shock protein 90 (HSP90) is a ubiquitously expressed chaperone that is
involved in the posttranslational folding and stability of proteins. Inhibition at the NH2 …

Our increasing understanding of cancer biology has led to the development of molecularly
targeted anticancer drugs. The full potential of these agents has not, however, been …

Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low
prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive …

Due to the critical role of heat shock protein 90 (HSP90) in regulating the stability, activity
and intracellular sorting of its client proteins involved in multiple oncogenic processes …

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination
With Carboplatin in Patients With Advanced Solid Tumors - PMC Back to Top Skip to main …